Papaefthymiou Apostolis, Gkolfakis Paraskevas, Basiliya Kirill, Facciorusso Antonio, Ramai Daryl, Gerges Christian, Tziatzios Georgios, Phillpotts Simon, Webster George J
Pancreaticobiliary Medicine Unit, University College London Hospitals (UCLH), London, United Kingdom (Apostolis Papaefthymiou, Kirill Basiliya, Simon Phillpotts, George J. Webster).
Department of Gastroenterology, "Konstantopoulio-Patision" General Hospital of Nea Ionia, Athens, Greece (Paraskevas Gkolfakis Georgios Tziatzios).
Ann Gastroenterol. 2024 Mar-Apr;37(2):225-234. doi: 10.20524/aog.2024.0869. Epub 2024 Feb 18.
Percutaneous cholangioscopy (PerC) offers an alternative for patients with an inaccessible biliary tree. This systematic review and meta-analysis aimed to evaluate the performance of this technique.
A search in Medline, Cochrane and ClinicalTrials.gov databases was performed for studies assessing PerC up to October 2022. The primary outcome was diagnostic success, defined as successful stone identification or stricture workup. Secondary outcomes included therapeutic success (stone extraction, stenting) and complication rate. A subgroup analysis compared previous-generation and modern cholangioscopes. We performed meta-analyses using a random-effects model and the results were reported as percentages with 95% confidence interval (CI).
Fourteen studies (682 patients) were eligible for analysis. The rate of diagnostic success was 98.7% (95%CI 97.6-99.8%; =31.19%) and therapeutic success was 88.6% (95%CI 82.8-94.3%; =74.92%). Adverse events were recorded in 17.1% (95%CI 10.7-23.5%; =77.56%), of which 15.9% (95%CI 9.8-21.9%; =75.98%) were minor and 0.6% (95%CI 0.1-1.2%; =0%) major. The Spyglass system showed null heterogeneity for all outcomes; compared with older-generation endoscopes it offered comparable diagnostic success, but yielded significantly superior therapeutic success (96.1%, 95%CI 90-100%; =0% vs. 86.4%, 95%CI 79.2-93.6%; =81.41%; P=0.02].
PerC, especially using currently available cholangioscopes, is associated with high diagnostic and therapeutic success.
经皮胆管镜检查(PerC)为胆管难以触及的患者提供了一种替代方法。本系统评价和荟萃分析旨在评估该技术的性能。
在Medline、Cochrane和ClinicalTrials.gov数据库中进行检索,以查找截至2022年10月评估PerC的研究。主要结局为诊断成功,定义为成功识别结石或对狭窄进行评估。次要结局包括治疗成功(结石取出、支架置入)和并发症发生率。亚组分析比较了上一代和现代胆管镜。我们使用随机效应模型进行荟萃分析,结果以百分比及95%置信区间(CI)报告。
14项研究(682例患者)符合分析条件。诊断成功率为98.7%(95%CI 97.6 - 99.8%;I² = 31.19%),治疗成功率为88.6%(95%CI 82.8 - 94.3%;I² = 74.92%)。不良事件发生率为17.1%(95%CI 10.7 - 23.5%;I² = 77.56%),其中15.9%(95%CI 9.8 - 21.9%;I² = 75.98%)为轻微不良事件,0.6%(95%CI 0.1 - 1.2%;I² = 0%)为严重不良事件。Spyglass系统在所有结局方面均显示无异质性;与上一代内镜相比,其诊断成功率相当,但治疗成功率显著更高(96.1%,95%CI 90 - 100%;I² = 0% 对比 86.4%,95%CI 79.2 - 93.6%;I² = 81.41%;P = 0.02)。
经皮胆管镜检查,尤其是使用当前可用的胆管镜,具有较高的诊断和治疗成功率。